You can buy Renib at the lowest price in the online pharmacy Nextgen.ooo . Regorafenib is a kinase inhibitor used to treat patients with metastatic colorectal cancer, unresectable, locally advanced or metastatic gastrointestinal stromal tumors and hepatocellular carcinoma. Regorafenib is an oral inhibitor of several kinases. It was approved by the FDA on September 27, 2012. In April 2017, the use of Regorafenib was expanded to treat hepatocellular carcinoma. Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and pathological processes such as oncogenesis, tumor angiogenesis and maintenance of the tumor microenvironment. In in vitro biochemical or cellular assays, regorafenib or its major active human metabolites M-2 and M-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E, SAPK2, PTK5, and Abl at clinically achieved regorafenib concentrations.
 
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) who have previously received imatinib mesylate and sunitinib malate. Regorafenib is also indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have previously received sorafenib.